These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 28363519)

  • 1. Pretargeting with bispecific fusion proteins facilitates delivery of nanoparticles to tumor cells with distinct surface antigens.
    Yang Q; Parker CL; Lin Y; Press OW; Park SI; Lai SK
    J Control Release; 2017 Jun; 255():73-80. PubMed ID: 28363519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multivalent interactions between streptavidin-based pretargeting fusion proteins and cell receptors impede efficient internalization of biotinylated nanoparticles.
    Parker CL; Yang Q; Yang B; McCallen JD; Park SI; Lai SK
    Acta Biomater; 2017 Nov; 63():181-189. PubMed ID: 28870833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants.
    Wilbur DS; Park SI; Chyan MK; Wan F; Hamlin DK; Shenoi J; Lin Y; Wilbur SM; Buchegger F; Pantelias A; Pagel JM; Press OW
    Bioconjug Chem; 2010 Jul; 21(7):1225-38. PubMed ID: 20597486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addressing challenges of heterogeneous tumor treatment through bispecific protein-mediated pretargeted drug delivery.
    Yang Q; Parker CL; McCallen JD; Lai SK
    J Control Release; 2015 Dec; 220(Pt B):715-26. PubMed ID: 26407672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved therapeutic results by pretargeted radioimmunotherapy of non-Hodgkin's lymphoma with a new recombinant, trivalent, anti-CD20, bispecific antibody.
    Sharkey RM; Karacay H; Litwin S; Rossi EA; McBride WJ; Chang CH; Goldenberg DM
    Cancer Res; 2008 Jul; 68(13):5282-90. PubMed ID: 18593929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted cell uptake of a noninternalizing antibody through conjugation to iron oxide nanoparticles in primary central nervous system lymphoma.
    Wang T; Kievit FM; Veiseh O; Arami H; Stephen ZR; Fang C; Liu Y; Ellenbogen RG; Zhang M
    World Neurosurg; 2013; 80(1-2):134-41. PubMed ID: 23298674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A pretargeted nanoparticle system for tumor cell labeling.
    Gunn J; Park SI; Veiseh O; Press OW; Zhang M
    Mol Biosyst; 2011 Mar; 7(3):742-8. PubMed ID: 21107453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretargeted radioimmunotherapy of cancer: progress step by step.
    Boerman OC; van Schaijk FG; Oyen WJ; Corstens FH
    J Nucl Med; 2003 Mar; 44(3):400-11. PubMed ID: 12621007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Double attack strategy for leukemia using a pre-targeting bispecific antibody (CD20 Ab-mPEG scFv) and actively attracting PEGylated liposomal doxorubicin to enhance anti-tumor activity.
    Ho KW; Chen IU; Cheng YA; Liao TY; Liu ES; Chen HJ; Lu YC; Su YC; Roffler SR; Huang BC; Liu HJ; Huang MY; Chen CY; Cheng TL
    J Nanobiotechnology; 2021 Jan; 19(1):16. PubMed ID: 33422061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of immunoscintigraphy, efficacy, and toxicity of conventional and pretargeted radioimmunotherapy in CD20-expressing human lymphoma xenografts.
    Subbiah K; Hamlin DK; Pagel JM; Wilbur DS; Meyer DL; Axworthy DB; Mallett RW; Theodore LJ; Stayton PS; Press OW
    J Nucl Med; 2003 Mar; 44(3):437-45. PubMed ID: 12621012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD20 monoclonal antibody targeted nanoscale drug delivery system for doxorubicin chemotherapy: an in vitro study of cell lysis of CD20-positive Raji cells.
    Jiang S; Wang X; Zhang Z; Sun L; Pu Y; Yao H; Li J; Liu Y; Zhang Y; Zhang W
    Int J Nanomedicine; 2016; 11():5505-5518. PubMed ID: 27843311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved therapy of non-Hodgkin's lymphoma xenografts using radionuclides pretargeted with a new anti-CD20 bispecific antibody.
    Sharkey RM; Karacay H; Chang CH; McBride WJ; Horak ID; Goldenberg DM
    Leukemia; 2005 Jun; 19(6):1064-9. PubMed ID: 15815716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy.
    Schultz J; Lin Y; Sanderson J; Zuo Y; Stone D; Mallett R; Wilbert S; Axworthy D
    Cancer Res; 2000 Dec; 60(23):6663-9. PubMed ID: 11118050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficient inhibition of human B-cell lymphoma in SCID mice by synergistic antitumor effect of human 4-1BB ligand/anti-CD20 fusion proteins and anti-CD3/anti-CD20 diabodies.
    Liu R; Jiang W; Yang M; Guo H; Zhang Y; Wang J; Zhu H; Shi R; Fan D; Yang C; Zhu Z; Xie Y; Xiong D
    J Immunother; 2010 Jun; 33(5):500-9. PubMed ID: 20463597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose.
    Förster GJ; Santos EB; Smith-Jones PM; Zanzonico P; Larson SM
    J Nucl Med; 2006 Jan; 47(1):140-9. PubMed ID: 16391198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intraperitoneal pretarget radioimmunotherapy with CC49 fusion protein.
    Buchsbaum DJ; Khazaeli MB; Axworthy DB; Schultz J; Chaudhuri TR; Zinn KR; Carpenter M; LoBuglio AF
    Clin Cancer Res; 2005 Nov; 11(22):8180-5. PubMed ID: 16299250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor-targeting antibody-anticalin fusion proteins for in vivo pretargeting applications.
    Steiner M; Gutbrodt K; Krall N; Neri D
    Bioconjug Chem; 2013 Feb; 24(2):234-41. PubMed ID: 23350721
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of administration route and dose of streptavidin or biotin on the tumor uptake of radioactivity in intraperitoneal tumor with multistep targeting.
    Zhang M; Yao Z; Sakahara H; Saga T; Nakamoto Y; Sato N; Zhao S; Nakada H; Yamashina I; Konishi J
    Nucl Med Biol; 1998 Feb; 25(2):101-5. PubMed ID: 9468023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL): initial phase I/II study results.
    Weiden PL; Breitz HB; Press O; Appelbaum JW; Bryan JK; Gaffigan S; Stone D; Axworthy D; Fisher D; Reno J
    Cancer Biother Radiopharm; 2000 Feb; 15(1):15-29. PubMed ID: 10740649
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conventional and pretargeted radioimmunotherapy using bismuth-213 to target and treat non-Hodgkin lymphomas expressing CD20: a preclinical model toward optimal consolidation therapy to eradicate minimal residual disease.
    Park SI; Shenoi J; Pagel JM; Hamlin DK; Wilbur DS; Orgun N; Kenoyer AL; Frayo S; Axtman A; Bäck T; Lin Y; Fisher DR; Gopal AK; Green DJ; Press OW
    Blood; 2010 Nov; 116(20):4231-9. PubMed ID: 20702781
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.